Long-term use of bisphosphonates in osteoporosis

References

1. ↵
   1. Black DM,
   2. Cummings SR,
   3. Karpf DB,
   4. Cauley JA,
   5. Thompson DE

   (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research. Lancet 348:1535–1541.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Black DM,
   2. Cummings SR,
   3. Karpf DB

   (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Fraser L,
   2. Adachi JD

   (2009) Glucocorticoid-induced osteoporosis: Treatment update and review. Ther Adv Musculoskelet Dis 1:71–85.

   OpenUrlCrossRefPubMed
4. ↵
   1. Black DM,
   2. Cummings SR,
   3. Karpf DB,
   4. Cauley JA,
   5. Thompson DE,
   6. Nevitt MC,
   7. et al.

   (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research. Lancet 348:1535–1541.

   OpenUrlCrossRefPubMedWeb of Science
5. 1. Black DM,
   2. Delmas PD,
   3. Eastell R,
   4. Reid IR,
   5. Boonen S,
   6. Cauley JA,
   7. et al.

   (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Black DM,
   2. Schwartz AV,
   3. Ensrud KE,
   4. Cauley JA,
   5. Levis S,
   6. Quandt SA,
   7. et al.

   (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Odvina CV,
   2. Zerwekh JE,
   3. Rao DS,
   4. Maalouf N,
   5. Gottschalk FA,
   6. Pak CY

   (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Shane E,
   2. Burr D,
   3. Ebeling PR,
   4. Abrahamsen B,
   5. Adler RA,
   6. Brown TD

   (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Jie Zhang Huifeng,
   2. Yun Nicole C

   (2011) Wright. Potential and Pitfalls of Using Large Administrative Claims Data to Study the Safety of Osteoporosis Therapies. Current Rheumatology Reports 3:273–282.

   OpenUrl
10. 1. Lenart BA,
    2. Lorich DG,
    3. Lane JM

    (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Mashiba T,
    2. Hirano T,
    3. Turner CH,
    4. Forwood MR,
    5. Johnston CC,
    6. Burr DB

    (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Mashiba T,
    2. Turner CH,
    3. Hirano T,
    4. Fowrood MR,
    5. Jacob DS,
    6. Johnston CC,
    7. et al.

    (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 28:524–531.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Fukuda F,
    2. Kurinomaru N,
    3. Hijioka A

    (2014) Weekly teriparatide for delayed unions of atypical subtrochanteric femur fractures. Biol Ther 4:73–79.

    OpenUrl
14. ↵
    1. Im GI,
    2. Lee SH

    (2015) Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 22:183–189.

    OpenUrlCrossRef
15. ↵
    1. Chiang CY,
    2. Zebaze RM,
    3. Ghasem-Zadeh A,
    4. Iuliano-Burns S,
    5. Hardidge A,
    6. Seeman E

    (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Chang ST,
    2. Tenforde AS,
    3. Grimsrud CD,
    4. O’Ryan FS,
    5. Gonzalez JR,
    6. Baer DM,
    7. et al.

    (2012) Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 51:524–527.

    OpenUrlCrossRefPubMedWeb of Science
17. 1. Ota S,
    2. Inoue R,
    3. Shiozaki T,
    4. Yamamoto Y,
    5. Hashimoto N,
    6. Takeda O,
    7. et al.

    (2016) Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer, 10.
18. ↵
    1. Lampropoulou-Adamidou K,
    2. Tournis S,
    3. Triantafyllopoulos IK

    (2016) Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. J Musculoskelet Neuronal Interact 16:75–78.

    OpenUrl
19. ↵
    1. Shane E,
    2. Burr D,
    3. Abrahamsen B,
    4. Adler R,
    5. Brown TD,
    6. Cheung AM,
    7. et al.

    (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23.

    OpenUrlCrossRefPubMed
20. ↵
    1. Adler RA,
    2. El-Hajj Fuleihan G,
    3. Bauer DC,
    4. Camacho PM,
    5. Clarke BL,
    6. Clines GA

    (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:1910.

    OpenUrl
21. ↵
    1. Schneider JP

    (2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61:31–33.

    OpenUrlPubMed